{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:51:00Z","timestamp":1790351460007,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic myeloid leukemia (CML) remains a therapeutic challenge, particularly in patients who develop resistance to standard tyrosine kinase inhibitors (TKIs) such as imatinib. Here, we present the first demonstration of the potent anti-leukemic activity of the histone deacetylase (HDAC) inhibitor martinostat in both TKI-sensitive and TKI-resistant CML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Structural and biochemical analyses confirmed the efficient and selective binding of martinostat to HDAC isoenzyme ligand-binding pockets, resulting in histone and tubulin hyperacetylation in both imatinib-sensitive and resistant CML cells, outperforming vorinostat, a clinically used HDAC inhibitor (HDACi). It selectively impaired CML cell proliferation and viability and induced apoptosis across various CML models, including resistant cell models and patient blasts, with minimal toxicity to healthy cells and low developmental toxicity in zebrafish. In addition to its single-agent efficacy, martinostat demonstrated enhanced anticancer effects when combined with imatinib, both in vitro and in vivo, significantly reducing tumor growth in resistant CML xenograft models. Mechanistically, mRNA-seq data showed that martinostat disrupted key survival signaling pathways and amplified apoptotic responses, contributing to its anticancer activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings highlight the potential of martinostat as a selective, low-toxicity HDACi that, combined with TKIs, could provide an effective strategy to overcome drug resistance in CML and improve therapeutic outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-025-01921-0","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T13:14:08Z","timestamp":1752671648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia"],"prefix":"10.1186","volume":"17","author":[{"given":"Haeun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Won","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lorant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aloran","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"Orlikova-Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cerella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christo","family":"Christov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag Erlend","family":"Olberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Bormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoung Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Woo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schnekenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Diederich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"issue":"1","key":"1921_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1921_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/cancers12020318","volume":"12","author":"H Losson","year":"2020","unstructured":"Losson H, Schnekenburger M, Dicato M, Diederich M. HDAC6-an emerging target against chronic myeloid leukemia? Cancers (Basel). 2020;12(2):318.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"1921_CR3","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022;97(9):1236\u201356.","journal-title":"Am J Hematol"},{"issue":"1","key":"1921_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/cells10010117","volume":"10","author":"VR Minciacchi","year":"2021","unstructured":"Minciacchi VR, Kumar R, Krause DS. Chronic myeloid leukemia: a model disease of the past, present and future. Cells. 2021;10(1):117.","journal-title":"Cells"},{"issue":"1","key":"1921_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","volume":"4","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, Han J, Wei X. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Sig Transduct Target Ther. 2019;4(1):62.","journal-title":"Sig Transduct Target Ther"},{"key":"1921_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3389\/fcell.2019.00136","volume":"7","author":"J Bugler","year":"2019","unstructured":"Bugler J, Kinstrie R, Scott MT, Vetrie D. Epigenetic reprogramming and emerging epigenetic therapies in CML. Front Cell Dev Biol. 2019;7:136.","journal-title":"Front Cell Dev Biol"},{"key":"1921_CR7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.semcancer.2017.07.006","volume":"51","author":"S Koschmieder","year":"2018","unstructured":"Koschmieder S, Vetrie D. Epigenetic dysregulation in chronic myeloid leukaemia: a myriad of mechanisms and therapeutic options. Semin Cancer Biol. 2018;51:180\u201397.","journal-title":"Semin Cancer Biol"},{"key":"1921_CR8","doi-asserted-by":"publisher","first-page":"576946","DOI":"10.3389\/fcell.2020.576946","volume":"8","author":"G Li","year":"2020","unstructured":"Li G, Tian Y, Zhu WG. The roles of histone deacetylases and their inhibitors in cancer therapy. Front Cell Dev Biol. 2020;8:576946.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1921_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","volume":"19","author":"P Wang","year":"2020","unstructured":"Wang P, Wang Z, Liu J. Role of HDACs in normal and malignant hematopoiesis. Mol Cancer. 2020;19(1):5.","journal-title":"Mol Cancer"},{"issue":"1","key":"1921_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13148-020-00839-z","volume":"12","author":"M Lernoux","year":"2020","unstructured":"Lernoux M, Schnekenburger M, Losson H, Vermeulen K, Hahn H, Gerard D, Lee JY, Mazumder A, Ahamed M, Christov C, et al. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL\/MYC-signaling: effect on imatinib resistance and stem cells. Clin Epigenet. 2020;12(1):69.","journal-title":"Clin Epigenet"},{"issue":"8","key":"1921_CR11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/cac2.12590","volume":"44","author":"M Schnekenburger","year":"2024","unstructured":"Schnekenburger M, Lorant A, Gajulapalli SR, Rajora R, Lee JY, Mazumder A, Yang H, Christov C, Kang HJ, Pirotte B, et al. Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia as an immunogenic anticancer strategy. Cancer Commun (Lond). 2024;44(8):915\u201320.","journal-title":"Cancer Commun (Lond)"},{"key":"1921_CR12","doi-asserted-by":"publisher","first-page":"105058","DOI":"10.1016\/j.phrs.2020.105058","volume":"160","author":"H Losson","year":"2020","unstructured":"Losson H, Gajulapalli SR, Lernoux M, Lee JY, Mazumder A, Gerard D, Seidel C, Hahn H, Christov C, Dicato M, et al. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia. Pharmacol Res. 2020;160:105058.","journal-title":"Pharmacol Res"},{"issue":"10","key":"1921_CR13","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1002\/cncr.32041","volume":"125","author":"M Schnekenburger","year":"2019","unstructured":"Schnekenburger M, Dicato M, Diederich MF. Anticancer potential of naturally occurring immunoepigenetic modulators: A promising avenue? Cancer. 2019;125(10):1612\u201328.","journal-title":"Cancer"},{"issue":"19","key":"1921_CR14","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","volume":"12","author":"W Fiskus","year":"2006","unstructured":"Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res. 2006;12(19):5869\u201378.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"1921_CR15","doi-asserted-by":"publisher","first-page":"7999","DOI":"10.1021\/jm500872p","volume":"57","author":"C Wang","year":"2014","unstructured":"Wang C, Schroeder FA, Wey HY, Borra R, Wagner FF, Reis S, Kim SW, Holson EB, Haggarty SJ, Hooker JM. In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs. J Med Chem. 2014;57(19):7999\u20138009.","journal-title":"J Med Chem"},{"issue":"1","key":"1921_CR16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1172\/JCI123743","volume":"129","author":"TM Gilbert","year":"2019","unstructured":"Gilbert TM, Zurcher NR, Wu CJ, Bhanot A, Hightower BG, Kim M, Albrecht DS, Wey HY, Schroeder FA, Rodriguez-Thompson A, et al. PET neuroimaging reveals histone deacetylase dysregulation in schizophrenia. J Clin Invest. 2019;129(1):364\u201372.","journal-title":"J Clin Invest"},{"issue":"1","key":"1921_CR17","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1038\/s41467-022-30653-5","volume":"13","author":"TA Pascoal","year":"2022","unstructured":"Pascoal TA, Chamoun M, Lax E, Wey HY, Shin M, Ng KP, Kang MS, Mathotaarachchi S, Benedet AL, Therriault J, et al. [(11)C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer\u2019s disease. Nat Commun. 2022;13(1):4171.","journal-title":"Nat Commun"},{"issue":"3","key":"1921_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/sj.leu.2404549","volume":"21","author":"E Diaz-Blanco","year":"2007","unstructured":"Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Rosskopf M, Brors B, Pechtel S, Bork S, Koch A, et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia. 2007;21(3):494\u2013504.","journal-title":"Leukemia"},{"issue":"5","key":"1921_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/FPC.0b013e328351f3e9","volume":"22","author":"R Benito","year":"2012","unstructured":"Benito R, Lumbreras E, Abaigar M, Gutierrez NC, Delgado M, Robledo C, Garcia JL, Rodriguez-Vicente AE, Canizo MC, Rivas JM. Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression. Pharmacogenet Genomics. 2012;22(5):381\u20138.","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"1921_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013;27(3):221\u201334.","journal-title":"J Comput Aided Mol Des"},{"issue":"6\u20137","key":"1921_CR21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10822-010-9349-1","volume":"24","author":"JR Greenwood","year":"2010","unstructured":"Greenwood JR, Calkins D, Sullivan AP, Shelley JC. Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J Comput Aided Mol Des. 2010;24(6\u20137):591\u2013604.","journal-title":"J Comput Aided Mol Des"},{"issue":"21","key":"1921_CR22","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 2006;49(21):6177\u201396.","journal-title":"J Med Chem"},{"issue":"7","key":"1921_CR23","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","volume":"17","author":"C Lu","year":"2021","unstructured":"Lu C, Wu C, Ghoreishi D, Chen W, Wang L, Damm W, Ross GA, Dahlgren MK, Russell E, Von Bargen CD, et al. OPLS4: Improving force field accuracy on challenging regimes of chemical space. J Chem Theory Comput. 2021;17(7):4291\u2013300.","journal-title":"J Chem Theory Comput"},{"issue":"1","key":"1921_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.canlet.2013.09.026","volume":"343","author":"C Seidel","year":"2014","unstructured":"Seidel C, Schnekenburger M, Dicato M, Diederich M. Antiproliferative and proapoptotic activities of 4-hydroxybenzoic acid-based inhibitors of histone deacetylases. Cancer Lett. 2014;343(1):134\u201346.","journal-title":"Cancer Lett"},{"key":"1921_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.canlet.2018.07.041","volume":"438","author":"A Mazumder","year":"2018","unstructured":"Mazumder A, Lee JY, Talhi O, Cerella C, Chateauvieux S, Gaigneaux A, Hong CR, Kang HJ, Lee Y, Kim KW, et al. Hydroxycoumarin OT-55 kills CML cells alone or in synergy with imatinib or Synribo: involvement of ER stress and DAMP release. Cancer Lett. 2018;438:197\u2013218.","journal-title":"Cancer Lett"},{"issue":"12","key":"1921_CR26","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1080\/15548627.2019.1596492","volume":"15","author":"SH Han","year":"2019","unstructured":"Han SH, Korm S, Han YG, Choi SY, Kim SH, Chung HJ, Park K, Kim JY, Myung K, Lee JY, et al. GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia. Autophagy. 2019;15(12):2076\u201390.","journal-title":"Autophagy"},{"issue":"15","key":"1921_CR27","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114\u201320.","journal-title":"Bioinformatics"},{"issue":"8","key":"1921_CR28","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37(8):907\u201315.","journal-title":"Nat Biotechnol"},{"issue":"D1","key":"1921_CR29","doi-asserted-by":"publisher","first-page":"D891","DOI":"10.1093\/nar\/gkad1049","volume":"52","author":"PW Harrison","year":"2024","unstructured":"Harrison PW, Amode MR, Austine-Orimoloye O, Azov AG, Barba M, Barnes I, Becker A, Bennett R, Berry A, Bhai J, et al. Ensembl 2024. Nucleic Acids Res. 2024;52(D1):D891\u20139.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"1921_CR30","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923\u201330.","journal-title":"Bioinformatics"},{"issue":"12","key":"1921_CR31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"1","key":"1921_CR32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate\u2014a practical and powerful approach to multiple testing. J R Stat Soc Ser B-Stat Methodol. 1995;57(1):289\u2013300.","journal-title":"J R Stat Soc Ser B-Stat Methodol"},{"issue":"6","key":"1921_CR33","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1080\/21691401.2017.1369423","volume":"46","author":"N Kumar","year":"2018","unstructured":"Kumar N, Tomar R, Pandey A, Tomar V, Singh VK, Chandra R. Preclinical evaluation and molecular docking of 1,3-benzodioxole propargyl ether derivatives as novel inhibitor for combating the histone deacetylase enzyme in cancer. Artif Cells Nanomed Biotechnol. 2018;46(6):1288\u201399.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"5","key":"1921_CR34","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1021\/acschemneuro.5b00297","volume":"7","author":"MG Strebl","year":"2016","unstructured":"Strebl MG, Wang C, Schroeder FA, Placzek MS, Wey HY, Van de Bittner GC, Neelamegam R, Hooker JM. Development of a fluorinated class-I HDAC radiotracer reveals key chemical determinants of brain penetrance. ACS Chem Neurosci. 2016;7(5):528\u201333.","journal-title":"ACS Chem Neurosci"},{"issue":"7","key":"1921_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1570180813666161101152943","volume":"14","author":"M Ahamed","year":"2017","unstructured":"Ahamed M, Vermeulen K, Schnekenburger M, Moltzau LR, Levy FO, Marton J, Froeyen M, Olberg DE, Diederich M, Bormans G. Synthesis, enzyme assays and molecular docking studies of fluorina ted bioisosteres of santacruzamate A as potential HDAC tracers. Lett Drug Des Discov. 2017;14(7):1\u201311.","journal-title":"Lett Drug Des Discov"},{"key":"1921_CR36","doi-asserted-by":"publisher","first-page":"1260545","DOI":"10.3389\/fimmu.2023.1260545","volume":"14","author":"N Holay","year":"2023","unstructured":"Holay N, Somma A, Duchow M, Soleimani M, Capasso A, Kottapalli S, Rios J, Giri U, Diamond J, Schreiber A, et al. Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy. Front Immunol. 2023;14:1260545.","journal-title":"Front Immunol"},{"issue":"7446","key":"1921_CR37","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature12111","volume":"496","author":"K Howe","year":"2013","unstructured":"Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, Collins JE, Humphray S, McLaren K, Matthews L, et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature. 2013;496(7446):498\u2013503.","journal-title":"Nature"},{"issue":"10","key":"1921_CR38","doi-asserted-by":"publisher","first-page":"e76340","DOI":"10.1371\/journal.pone.0076340","volume":"8","author":"HW Chiu","year":"2013","unstructured":"Chiu HW, Yeh YL, Wang YC, Huang WJ, Chen YA, Chiou YS, Ho SY, Lin P, Wang YJ. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. PLoS ONE. 2013;8(10):e76340.","journal-title":"PLoS ONE"},{"issue":"10","key":"1921_CR39","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1002\/ijc.30664","volume":"140","author":"JM Shieh","year":"2017","unstructured":"Shieh JM, Tang YA, Hu FH, Huang WJ, Wang YJ, Jen J, Liao SY, Lu YH, Yeh YL, Wang TW, et al. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer. Int J Cancer. 2017;140(10):2375\u201386.","journal-title":"Int J Cancer"},{"issue":"3","key":"1921_CR40","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","volume":"111","author":"G Garcia-Manero","year":"2008","unstructured":"Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111(3):1060\u20136.","journal-title":"Blood"},{"issue":"3","key":"1921_CR41","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1080\/15384047.2018.1529093","volume":"20","author":"SE Ghayad","year":"2019","unstructured":"Ghayad SE, Rammal G, Sarkis O, Basma H, Ghamloush F, Fahs A, Karam M, Harajli M, Rabeh W, Mouawad JE, et al. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma. Cancer Biol Ther. 2019;20(3):272\u201383.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"1921_CR42","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1038\/s41598-018-21835-7","volume":"8","author":"N Marroncelli","year":"2018","unstructured":"Marroncelli N, Bianchi M, Bertin M, Consalvi S, Saccone V, De Bardi M, Puri PL, Palacios D, Adamo S, Moresi V. HDAC4 regulates satellite cell proliferation and differentiation by targeting P21 and Sharp1 genes. Sci Rep. 2018;8(1):3448.","journal-title":"Sci Rep"},{"issue":"3","key":"1921_CR43","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2159-8290.CD-19-0116","volume":"10","author":"P Mondello","year":"2020","unstructured":"Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discov. 2020;10(3):440\u201359.","journal-title":"Cancer Discov"},{"issue":"24","key":"1921_CR44","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1042\/BCJ20180465","volume":"475","author":"C Draney","year":"2018","unstructured":"Draney C, Austin MC, Leifer AH, Smith CJ, Kener KB, Aitken TJ, Hess KH, Haines AC, Lett E, Hernandez-Carretero A, et al. HDAC1 overexpression enhances beta-cell proliferation by down-regulating Cdkn1b\/p27. Biochem J. 2018;475(24):3997\u20134010.","journal-title":"Biochem J"},{"issue":"3","key":"1921_CR45","doi-asserted-by":"publisher","first-page":"e12447","DOI":"10.1111\/cpr.12447","volume":"51","author":"H Zhou","year":"2018","unstructured":"Zhou H, Cai Y, Liu D, Li M, Sha Y, Zhang W, Wang K, Gong J, Tang N, Huang A, et al. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21(Waf1\/Cip1) and p19(INK4d) upregulation in hepatocellular carcinoma. Cell Prolif. 2018;51(3):e12447.","journal-title":"Cell Prolif"},{"issue":"9","key":"1921_CR46","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.3390\/ijms20092271","volume":"20","author":"SH Chen","year":"2019","unstructured":"Chen SH, Chow JM, Hsieh YY, Lin CY, Hsu KW, Hsieh WS, Chi WM, Shabangu BM, Lee CH. HDAC1,2 knock-out and HDACi Induced cell apoptosis in imatinib-resistant K562 cells. Int J Mol Sci. 2019;20(9):2271.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1921_CR47","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41375-018-0117-x","volume":"32","author":"B Wingelhofer","year":"2018","unstructured":"Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, Muller M, Moriggl R. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia. 2018;32(8):1713\u201326.","journal-title":"Leukemia"},{"issue":"22","key":"1921_CR48","doi-asserted-by":"publisher","first-page":"8460","DOI":"10.3390\/ijms21228460","volume":"21","author":"MY Kim","year":"2020","unstructured":"Kim MY, Yan B, Huang S, Qiu Y. Regulating the regulators: the role of histone deacetylase 1 (HDAC1) in erythropoiesis. Int J Mol Sci. 2020;21(22):8460.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1921_CR49","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1093\/nar\/gkv188","volume":"43","author":"S Pinz","year":"2015","unstructured":"Pinz S, Unser S, Buob D, Fischer P, Jobst B, Rascle A. Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function. Nucleic Acids Res. 2015;43(7):3524\u201345.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"1921_CR50","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s10637-019-00794-4","volume":"38","author":"X Hao","year":"2020","unstructured":"Hao X, Xing W, Yuan J, Wang Y, Bai J, Bai J, Zhou Y. Cotargeting the JAK\/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms. Invest New Drugs. 2020;38(3):610\u201320.","journal-title":"Invest New Drugs"},{"issue":"23","key":"1921_CR51","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.7150\/jca.34972","volume":"10","author":"H Wu","year":"2019","unstructured":"Wu H, Yin J, Ai Z, Li G, Li Y, Chen L. Overexpression of miR-4433 by suberoylanilide hydroxamic acid suppresses growth of CML cells and induces apoptosis through targeting Bcr-Abl. J Cancer. 2019;10(23):5671\u201380.","journal-title":"J Cancer"},{"issue":"1","key":"1921_CR52","first-page":"20","volume":"6","author":"AA Able","year":"2017","unstructured":"Able AA, Burrell JA, Stephens JM. STAT5-interacting proteins: a synopsis of proteins that regulate STAT5 activity. Biology (Basel). 2017;6(1):20.","journal-title":"Biology (Basel)"},{"issue":"2","key":"1921_CR53","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1039\/C9RA07971H","volume":"10","author":"T Zhang","year":"2020","unstructured":"Zhang T, Wei D, Lu T, Ma D, Yu K, Fang Q, Zhang Z, Wang W, Wang J. CAY10683 and imatinib have synergistic effects in overcoming imatinib resistance via HDAC2 inhibition in chronic myeloid leukemia. RSC Adv. 2020;10(2):828\u201344.","journal-title":"RSC Adv"},{"issue":"7","key":"1921_CR54","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/cas.12965","volume":"107","author":"Y Matsuda","year":"2016","unstructured":"Matsuda Y, Yamauchi T, Hosono N, Uzui K, Negoro E, Morinaga K, Nishi R, Yoshida A, Kimura S, Maekawa T, et al. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells. Cancer Sci. 2016;107(7):1029\u201338.","journal-title":"Cancer Sci"},{"issue":"8","key":"1921_CR55","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/leu.2009.60","volume":"23","author":"P Gamas","year":"2009","unstructured":"Gamas P, Marchetti S, Puissant A, Grosso S, Jacquel A, Colosetti P, Pasquet JM, Mahon FX, Cassuto JP, Auberger P. Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells. Leukemia. 2009;23(8):1500\u20136.","journal-title":"Leukemia"},{"key":"1921_CR56","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2147\/DDDT.S132092","volume":"11","author":"P Xin","year":"2017","unstructured":"Xin P, Li C, Zheng Y, Peng Q, Xiao H, Huang Y, Zhu X. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines. Drug Des Devel Ther. 2017;11:1115\u201326.","journal-title":"Drug Des Devel Ther"},{"key":"1921_CR57","first-page":"145","volume-title":"Cell biology and translational medicine, volume 16: stem cells in tissue regeneration, therapy and drug discovery","author":"B Larijani","year":"2022","unstructured":"Larijani B, Hamidpour SK, Tayanloo-Beik A, Shahbazbadr A, Yavari H, Namazi N, Biglar M, Arjmand B. An overview of zebrafish modeling methods in drug discovery and development. In: Turksen K, editor. Cell biology and translational medicine, volume 16: stem cells in tissue regeneration, therapy and drug discovery. Cham: Springer; 2022. p. 145\u201369."},{"issue":"2","key":"1921_CR58","first-page":"614","volume":"106","author":"J Yao","year":"2021","unstructured":"Yao J, Xu L, Aypar U, Meyerson HJ, Londono D, Gao Q, Baik J, Dietz J, Benayed R, Sigler A, et al. Myeloid\/lymphoid neoplasms with eosinophilia\/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition. Haematologica. 2021;106(2):614\u20138.","journal-title":"Haematologica"},{"key":"1921_CR59","doi-asserted-by":"publisher","first-page":"1610570","DOI":"10.3389\/pore.2022.1610570","volume":"28","author":"E Stukaite-Ruibiene","year":"2022","unstructured":"Stukaite-Ruibiene E, Norvilas R, Dirse V, Stankeviciene S, Vaitkeviciene GE. Case Report: specific ABL-inhibitor imatinib is an effective targeted agent as the first line therapy to treat B-cell acute lymphoblastic leukemia with a cryptic NUP214::ABL1 gene fusion. Pathol Oncol Res. 2022;28:1610570.","journal-title":"Pathol Oncol Res"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01921-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-01921-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01921-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:50:47Z","timestamp":1757253047000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-01921-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1921"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-01921-0","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards (see Materials and Methods section for details).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"While preparing this manuscript, the author(s) used Grammarly.com and ChatGPT to improve language and readability. After using this tool\/service, the author(s) reviewed and edited the content as needed and took full responsibility for the publication's content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}